Valuation : Atossa Therapeutics, Inc.

Market Cap 25.05M 21.58M 20.43M 18.52M 34.75M 2.39B 34.92M 243M 93.33M 1.22B 94.07M 92.01M 3.85B P/E 2026 *
-0.65x
P/E 2027 * -0.8x
Enterprise Value 25.05M 21.58M 20.43M 18.52M 34.75M 2.39B 34.92M 243M 93.33M 1.22B 94.07M 92.01M 3.85B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.3%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Atossa Therapeutics, Inc.

1 day+7.26%
1 week-0.40%
Current month+0.40%
1 month+6.81%
3 months+2.03%
6 months-50.30%
Current year-71.64%
1 week 2.33
Extreme 2.33
2.61
1 month 2.32
Extreme 2.317
2.97
Current year 1.7
Extreme 1.7
10.95
1 year 1.7
Extreme 1.7
19.35
3 years 1.7
Extreme 1.7
34.65
5 years 1.7
Extreme 1.7
54.3
10 years 1.7
Extreme 1.7
468
Manager TitleAgeSince
Chief Executive Officer 75 2009-03-31
Director of Finance/CFO 50 2025-10-13
Chief Tech/Sci/R&D Officer - 2025-09-30
Director TitleAgeSince
Chairman 75 2009-03-31
Director/Board Member 64 2009-03-31
Director/Board Member 79 2011-06-30
Date Insider Type Main position Quantity % Market Cap. Importance
5/12/26
Ensisheim Partners LLC
OtherCompany 0 0% -
5/12/26 Free

Director

10,000 0.1161%
5/12/26 Free

Director

10,000 0.1161%
Change 5-day change 1-year change 3-year change Capi.($)
+7.26%-0.40%-80.07%-79.59% 25.05M
-0.71%-6.35%-2.99%+9.59% 45.48B
+0.21%-2.98%+337.74%+519.55% 43.68B
+1.74%-2.24%+39.82%+20.76% 43.09B
+1.38%-3.28%+6.84%+67.62% 39.4B
-1.44%-5.26%+8.97%+39.76% 31.91B
+0.87%-2.60% - - 17.31B
+0.75%-0.64%+19.75%+110.17% 16.4B
-0.31%-2.78%+10.78%+31.02% 14.24B
+1.93%-3.55%+82.00%+41.17% 13.28B
Average +1.17%-3.26%+46.98%+84.45% 26.48B
Weighted average by Cap. +0.41%-3.67%+74.55%+124.24%

Financials

2026 *2027 *
Net sales - -
Net income -34.89M -30.06M -28.47M -25.8M -48.41M -3.33B -48.65M -338M -130M -1.7B -131M -128M -5.36B -38.03M -32.76M -31.02M -28.12M -52.75M -3.63B -53.02M -368M -142M -1.85B -143M -140M -5.84B
Net Debt - -
Logo Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Employees
16
Date Price Change Volume
26-09-11 $2.510 +7.26% 60,410
26-09-10 $2.340 -2.50% 47,238
26-09-09 $2.400 -4.57% 24,800
26-09-08 $2.515 -0.20% 41,370
26-09-04 $2.520 -0.40% 28,028
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.510USD
Average target price
18.67USD
Spread / Average Target
+643.69%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATOS Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!